Artwork

Content provided by Heartland Institute and The Heartland Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Heartland Institute and The Heartland Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Consumers Have Spent Billions on Decongestants that Don’t Work

21:04
 
Share
 

Manage episode 394345598 series 8092
Content provided by Heartland Institute and The Heartland Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Heartland Institute and The Heartland Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Health Care News, we delve into the recent revelation by the Food and Drug Administration (FDA) that certain over-the-counter decongestants, specifically those labeled with "PE" (phenylephrine), are no more effective than a placebo. Our guest, Dr. Jeffrey Singer, a practicing surgeon from Phoenix, Arizona, and a senior fellow at the Cato Institute, sheds light on how these medications found their way onto store shelves.

Dr. Singer traces the issue back to the Combat Methamphetamine Epidemic Act (CMEA), enacted 18 years ago in response to the methamphetamine crisis. This legislation pushed pseudoephedrine, an effective decongestant, behind the counter, leading drug companies to modify their formulas to include PE for over-the-counter sales.

Throughout the episode, Dr. Singer discusses several key points:

  • The factors that led the FDA to reconsider its stance on over-the-counter decongestants.
  • An overview of different decongestant drugs and tips for consumers to differentiate them.
  • The process for purchasing pseudoephedrine, the effective decongestant.
  • An exploration of why the FDA initially overlooked the ineffectiveness of PE.
  • The sales strategies of drug manufacturers for OTC decongestants.
  • Evaluating the CMEA's impact on the Meth epidemic.
  • The potential for a class-action lawsuit against this misleading practice.
  • The future: Is there a possibility that Congress will repeal the CMEA?

For further insights, don't miss Dr. Singer’s op-ed in Health Care News, linked in the episode description.

  continue reading

97 episodes

Artwork
iconShare
 
Manage episode 394345598 series 8092
Content provided by Heartland Institute and The Heartland Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Heartland Institute and The Heartland Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode of Health Care News, we delve into the recent revelation by the Food and Drug Administration (FDA) that certain over-the-counter decongestants, specifically those labeled with "PE" (phenylephrine), are no more effective than a placebo. Our guest, Dr. Jeffrey Singer, a practicing surgeon from Phoenix, Arizona, and a senior fellow at the Cato Institute, sheds light on how these medications found their way onto store shelves.

Dr. Singer traces the issue back to the Combat Methamphetamine Epidemic Act (CMEA), enacted 18 years ago in response to the methamphetamine crisis. This legislation pushed pseudoephedrine, an effective decongestant, behind the counter, leading drug companies to modify their formulas to include PE for over-the-counter sales.

Throughout the episode, Dr. Singer discusses several key points:

  • The factors that led the FDA to reconsider its stance on over-the-counter decongestants.
  • An overview of different decongestant drugs and tips for consumers to differentiate them.
  • The process for purchasing pseudoephedrine, the effective decongestant.
  • An exploration of why the FDA initially overlooked the ineffectiveness of PE.
  • The sales strategies of drug manufacturers for OTC decongestants.
  • Evaluating the CMEA's impact on the Meth epidemic.
  • The potential for a class-action lawsuit against this misleading practice.
  • The future: Is there a possibility that Congress will repeal the CMEA?

For further insights, don't miss Dr. Singer’s op-ed in Health Care News, linked in the episode description.

  continue reading

97 episodes

Wszystkie odcinki

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide